Enveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoY
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.76) per share. This is a 93.47 percent increase over losses of $(11.64) per share from the same period last year.
Stocks · News reference
Enveric Biosciences Receives U.S. Patent Office Notice Of Allowance For An Application Covering Novel Compounds Within Its EVM401 Series Of Drug Candidates
The EVM401 Series comprises proprietary, non-hallucinogenic mescaline-derived compounds designed to promote neuroplasticity for the potential treatment of psychiatric and neurological disorders.The patent application,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Enveric Biosciences, Inc. (ENVB)
Filed: 2026-08-14 AccNo: 0001493152-26-038385 Size: 260 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.